World Health Organization

Slides:



Advertisements
Similar presentations
Pharmacovigilance Shanthi Pal, M.Pharmacy, PhD
Advertisements

Safety Reporting IN Clinical Trials
Walsall Healthcare NHS Trust Medicines Management.
Technical Briefing Seminar September |1 | The need for Pharmacovigilance Mary R Couper and Shanthi Pal Quality Assurance and Safety of Medicines.
OPTIMISING MEDICINES USE GRAHAM DAVIES Professor of Clinical Pharmacy & Therapeutics Institute of Pharmaceutical Science King’s College London.
Objectives Why we need DHCPL Situations that call for a DHCPL Definitions DHCPL itself–content, presentation, process Target audience Current and future.
An ABC of Drug-Related Problems RHB Meyboom, M Lindquist, ACG Egberts Drug Safety 2000;22:
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
ADVERSE EFFECTS OF DRUGS Phase II May Adverse Drug Reaction An adverse reaction to a drug is a harmful or unintended response. ADRs are claimed.
PHARMACOVIGILANCE AND CLINICAL TRIALS DIVISION 20 August 2015 Victoria Falls Protecting Your Right to Quality Medicines and Medical Devices.
Responsibilities of state, community and private sector on research ethic Policy : looking back on recent CCR5 antagonists Hugues Fischer, TRT-5 (French.
Study Designs in Epidemiologic
WORD GOD END’S WITH ALPHABET "D“ WORD DRUG END’S WITH ALPHABET "G"
Sten Olsson WHO Programme Expert Uppsala Monitoring Centre Sweden
Application of Pharmacovigilance in post- marketing traditional Chinese medicine Hua-Wen Xin Wuhan General Hospital, Wuhan, China.
Problems of Polypharmacy
Social Pharmacy Lecture no. 6 Rational use of drugs Dr. Padma GM Rao
METHODS TO STUDY DRUG SAFETY PROBLEMS animal experiments clinical trials epidemiological methods –spontaneous reporting case reports case series –Post-Marketing.
Definitions. Clinical pharmacy is the branch of Pharmacy where pharmacists provide patient care that optimizes the use of medication and promotes health,
Technical Briefing Seminar September |1 | Methods to study medicine safety problems Mary R Couper Quality Assurance and Safety of Medicines.
Dr Shanthi Pal Quality Assurance and Safety of Medicines WHO
In the early 1900 s Paul Ehrlich described an ideal drug as a magic bullet. magic bullet. Such a drug would be aimed precisely at a disease site and would.
PV of ARVs, November 2009, Dar Es Salaam 1 |1 | The need for Pharmacovigilance Shanthi Pal Quality Assurance and Safety of Medicines.
Signal identification and development I.Ralph Edwards.
Dr Mary Couper Quality Assurance and Safety of Medicines WHO
Pharmacovigilance WHO definition
European Patients’ Academy on Therapeutic Innovation Introduction to pharmacovigilance Monitoring the safety of medicines.
The Role of Healthcare Professionals in ADR reporting Michael Bonett Post-Licensing Section Medicines Authority.
27 June 2000Victor F. C. Raczkowski, M.D.1 Risk-Management Options Victor F. C. Raczkowski, M.D., M.S. Gastrointestinal Drugs Advisory Committee 27 June.
Why do we need Pharmacovigilance?
Drug Safety Assessment using Dubai Real World Claims Database (DRWD) April 2016 Dr Sangameshwar B Mahagaonkar MBBS, MD, DNB Engagement Manager, Real World.
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
Off-label Use.
Social Pharmacy and Pharmacovigilance
Principles of Risk Management
Detection & monitoring of ADR
Efficacy and Safety of Medicines
Why do we need Pharmacovigilance?
به نام و یاد خالق هستی هم او که آفرید شور و مستی.
8. Causality assessment:
Prescribing.
Pharmacovigilance: Tool for safe medication
Medication Reconciliation in Continuing Care
3. Key definitions Multi-partner training package on active TB drug safety monitoring and management (aDSM) July 2016.
Introduction to Clinical Pharmacy
All Wales Therapeutics and Toxicology Centre Cardiff, Wales, UK
Pharmacovigilance in clinical trials
Pharmacovigilance Dr. SURENDRA.S.AKASH MD.
عناوین برنامه واهداف ADR ونقش آن در ایمنی دارویی محاسبات دارویی
9. Introduction to signal detection
Quality Assurance and Safety of Medicines
Developing pharmacovigilance: new challenges and opportunities Mary Couper and Shanthi Pal Quality Assurance and Safety of Medicines.
The use of cotrimoxazole prophylaxis in the context of HIV infection
CD-JEV AEFI monitoring
Pharmacovigilance (PV)
به نام و یاد خالق هستی هم او که آفرید شور و مستی.
Home First.
68.3 million errors (28% of total) cause moderate or serious harm
Pharmacovigilance What? (2.6) Ensure ADR monitoring (Spontaneous reporting/Cohort studies) Who? Healthcare workers How? WHO International Drug Monitoring.
Is Alcohol a Problem? -Setting the Scene
Patient details Health number: this may be a national identifier (preferred), hospital, clinic, or program number Name: full name is preferable as an accurate.
Pharmacovigilance & Adverse Drug Reactions Dr. Habab Khalid Elkheir
Pharmacovigilance Systems: Drug Safety Surveillance
The Need for Pharmaco-Epidemiology in Health Services Research
Medicines Safety Mary R. Couper
Quality Assurance and Safety of Medicines
Dr Tim England TICH-2 SAE adjudicator
CPOE Medication errors resulting in preventable ADEs most commonly occur at the prescribing stage. Bobb A, et al. The epidemiology of prescribing errors:
Pharmacovigilance.
Adverse Event Analysis
Presentation transcript:

World Health Organization 22 May 2018 The need for Pharmacovigilance Mary R Couper and Shanthi Pal Quality Assurance and Safety of Medicines

World Health Organization Medicine Safety 22 May 2018 To undergo treatment you have to be very healthy, because apart from your sickness you have to withstand the medicine. Molière

Risk No medicinal product is entirely or absolutely safe for all people, in all places, at all times. We must always live with some measure of uncertainty.

What is Pharmacovigilance? World Health Organization What is Pharmacovigilance? 22 May 2018 WHO definition: The science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. This applies throughout the life cycle of a medicine equally to the pre-approval stage as to the post-approval.

Pharmaco - Vigilance Pharmaco = medicine Vigilare = to watch alert watchfulness forbearance of sleep; wakefulness watchfulness in respect of danger; care; caution; circumspection the process of paying close and continuous attention

What is the scope of pharmacovigilance? improve patient care and safety in relation to the use of medicines, and all medical and paramedical interventions, improve public health and safety in relation to the use of medicines, contribute to the assessment of benefit, harm, effectiveness and risk of medicines, encouraging their safe, rational and more effective (including cost-effective) use, and promote understanding, education and clinical training in pharmacovigilance and its effective communication to the public

Adverse event/experience – WHO definition Any untoward medical occurrence that may present during treatment with a pharmaceutical product but which does not necessarily have a causal relationship with this treatment

Adverse Reaction to a medicine (ADR) –WHO Definition A reaction which is noxious and unintended, and which occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for the modification of physiological function

Why do we need pharmacovigilance?

1959 / 61– Epidemia de focomelia por Talidomida (4. 000 – 10 1959 / 61– Epidemia de focomelia por Talidomida (4.000 – 10.000 casos no mundo, com 15% de mortos)

Why do we need pharmacovigilance? Reason 1: Humanitarian concern – Insufficient evidence of safety from clinical trials Animal experiments Phase 1 – 3 studies prior to marketing authorization

Drug Development

Limitations of phase 1 -3 clinical trials limited size: no more than 5000 and often as little as 500 volunteers narrow population: age and sex specific narrow indications: only the specific disease studied short duration: often no longer than a few weeks

Examples of product recalls due to toxicity Medicine Year Thalidomide 1965 Practolol 1975 Clioquinol 1970 Benoxaprofen 1982 Terfenadine 1997 Rofecoxib 2004 Veralipride 2007 Examples of serious and unexpected adverse events leading to withdrawal of medicine Phocomelia Sclerosing peritonitis Subacute nephropathy Nephrotoxicity, cholestatic jaundice Torsade de pointes Cardiovascular effects Anxiety, depression, movement disorders

Why do we need pharmacovigilance? Reason 2 Medicines are supposed to save lives Dying from a disease is sometimes unavoidable; dying from a medicine is unacceptable. Lepakhin V. Geneva 2005

UK: US: It has been suggested that ADRs may cause 5700 deaths per year in UK. Pirmohamed et al, 2004 ADRs were 4th-6th commonest cause of death in the US in 1994 Lazarou et al, 1998

World Health Organization 22 May 2018 125 Patients 24 Patients experienced ADRs (19%) Intro 2 (59%) were avoidable

Why do we need pharmacovigilance? Reason 3: ADRs are expensive !!

Cost £446 million per annum 6.5% of admissions are due to ADRs Seven 800-bed hospitals are occupied by ADR patients Cost £446 million per annum

Cost of ADRs in the US? Cost of drug related morbidity and mortality exceeded $177.4 billion in 2000 (Ernst FR & Grizzle AJ, 2001: J American Pharm. Assoc) ADR related cost to the country exceeds the cost of the medications themselves

Why do we need pharmacovigilance? Reason 4: Promoting rational use of medicines and adherence

HIV Clinic 2005 Re: Mr Joseph Bloggs Prescription Dr A. Who 31 December 2000 Re: Mr Joseph Bloggs  1)     abacavir + lamivudine + zidovudine 1 BD 2)       atenolol 100 mg/d 3)      acetylsalicylic acid 150mg/d 4)      cerivastatin 10 mg/d  5) gemfibrozil 200 mg/d 6) metformin 500 mg/d 7) fluoxetine 50 mg/d Sildenafil   HIV Clinic 2005

Italian Cohort Main reasons of discontinuation of first HAART regimen within 1st year: ICONA I C O N A Naive Antiretroviral Monforte et al. AIDS 1999

Why do we need pharmacovigilance? Reason 5: Ensuring public confidence If something can go wrong, it will – Murphy's law

World Health Organization 22 May 2018 ALLEGATION: Known about SSRI prescribing at unsafe doses for a decade disaster!! Guardian Weekly March 18-24 2004

Safety concerns now high on the agenda of ALL countries World Health Organization Safety concerns now high on the agenda of ALL countries 22 May 2018 Developed countries Developing countries PV in Emerging Countries, CPT2008 29th July 2008 Need for Pharmacovigilance Freetown, Sierra Leone 19th Aug. 2008 29 29 29

Why do we need pharmacovigilance? Reason 6: Ethics To know of something that is harmful to another person who does not know, and not telling, is unethical

Consequence Not reporting a serious unknown reaction is unethical valid for everyone patient health professional manufacturer authorities

Pharmacovigilance is Essential